JP2017525698A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017525698A5 JP2017525698A5 JP2017508075A JP2017508075A JP2017525698A5 JP 2017525698 A5 JP2017525698 A5 JP 2017525698A5 JP 2017508075 A JP2017508075 A JP 2017508075A JP 2017508075 A JP2017508075 A JP 2017508075A JP 2017525698 A5 JP2017525698 A5 JP 2017525698A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- residues
- fusion protein
- sirpα
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108060003951 Immunoglobulin Proteins 0.000 claims 37
- 102000018358 immunoglobulin Human genes 0.000 claims 37
- 108020001507 fusion proteins Proteins 0.000 claims 29
- 102000037865 fusion proteins Human genes 0.000 claims 29
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims 28
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims 28
- 239000000427 antigen Substances 0.000 claims 11
- 102000036639 antigens Human genes 0.000 claims 11
- 108091007433 antigens Proteins 0.000 claims 11
- 210000003743 erythrocyte Anatomy 0.000 claims 8
- 229960005395 cetuximab Drugs 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 238000012986 modification Methods 0.000 claims 4
- 230000004048 modification Effects 0.000 claims 4
- 210000004881 tumor cell Anatomy 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 102220470105 Amidophosphoribosyltransferase_Q37H_mutation Human genes 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 108010058590 CD47 Antigen Proteins 0.000 claims 1
- 102000006355 CD47 Antigen Human genes 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 210000000270 basal cell Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- 229950002140 futuximab Drugs 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 229950008001 matuzumab Drugs 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 210000001989 nasopharynx Anatomy 0.000 claims 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 1
- 229950010203 nimotuzumab Drugs 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102220266399 rs1555186817 Human genes 0.000 claims 1
- 102220024927 rs199472833 Human genes 0.000 claims 1
- 102200145334 rs2274084 Human genes 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462038196P | 2014-08-15 | 2014-08-15 | |
| US62/038,196 | 2014-08-15 | ||
| PCT/EP2015/068798 WO2016024021A1 (en) | 2014-08-15 | 2015-08-14 | Sirp-alpha immunoglobulin fusion proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017525698A JP2017525698A (ja) | 2017-09-07 |
| JP2017525698A5 true JP2017525698A5 (enExample) | 2018-09-20 |
| JP6764858B2 JP6764858B2 (ja) | 2020-10-07 |
Family
ID=53872055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017508075A Expired - Fee Related JP6764858B2 (ja) | 2014-08-15 | 2015-08-14 | Ｓｉｒｐ−アルファ免疫グロブリン融合タンパク質 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US11021694B2 (enExample) |
| EP (2) | EP3180363B2 (enExample) |
| JP (1) | JP6764858B2 (enExample) |
| KR (1) | KR20170036796A (enExample) |
| CN (1) | CN107108748A (enExample) |
| AU (1) | AU2015303135B2 (enExample) |
| BR (1) | BR112017002646A2 (enExample) |
| CA (1) | CA2956126A1 (enExample) |
| DK (1) | DK3180363T3 (enExample) |
| ES (1) | ES2751915T5 (enExample) |
| HR (1) | HRP20191872T1 (enExample) |
| HU (1) | HUE046661T2 (enExample) |
| IL (1) | IL250622B2 (enExample) |
| LT (1) | LT3180363T (enExample) |
| MX (1) | MX377196B (enExample) |
| PL (1) | PL3180363T3 (enExample) |
| PT (1) | PT3180363T (enExample) |
| RU (1) | RU2017108203A (enExample) |
| SG (1) | SG11201701189TA (enExample) |
| SI (1) | SI3180363T1 (enExample) |
| WO (1) | WO2016024021A1 (enExample) |
| ZA (1) | ZA201701810B (enExample) |
Families Citing this family (140)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME03550B (me) | 2012-12-17 | 2020-07-20 | Trillium Therapeutics Inc | Lečenje cd47+ obolelih ćelija sa sirp alfa-fc fuzijama |
| EP2970485A1 (en) * | 2013-03-15 | 2016-01-20 | Merck Patent GmbH | Tetravalent bispecific antibodies |
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| HRP20210977T1 (hr) | 2014-02-10 | 2021-09-17 | Merck Patent Gmbh | Ciljano inhibiranje tgf beta |
| ES2751915T5 (es) | 2014-08-15 | 2022-12-23 | Merck Patent Gmbh | Proteínas de fusión de inmunoglobulina con SIRP alfa |
| SG11201707182WA (en) * | 2015-03-05 | 2017-10-30 | Hutchinson Fred Cancer Res | Immunomodulatory fusion proteins and uses thereof |
| RU2740672C2 (ru) | 2015-08-07 | 2021-01-19 | ЭйЭлЭкс Онколоджи Инк. | Конструкции, имеющие sirp-альфа домен или его вариант |
| SG10201913573UA (en) | 2015-10-01 | 2020-03-30 | Heat Biologics Inc | Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins |
| CN107149682B (zh) * | 2016-03-04 | 2022-01-04 | 复旦大学 | 一种靶向cd47的免疫检查点抑制剂药物组合物及其制备方法 |
| WO2017184553A1 (en) * | 2016-04-18 | 2017-10-26 | Baylor College Of Medicine | Cancer gene therapy targeting cd47 |
| US11560433B2 (en) | 2016-05-27 | 2023-01-24 | Albert Einstein College Of Medicine | Methods of treatment by targeting VCAM1 and MAEA |
| CN107459578B (zh) * | 2016-05-31 | 2021-11-26 | 泰州迈博太科药业有限公司 | 一种靶向cd47与pd-l1的双功能融合蛋白 |
| WO2018008470A1 (ja) * | 2016-07-05 | 2018-01-11 | 国立大学法人神戸大学 | 抗腫瘍剤 |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| SG10201913263SA (en) | 2016-09-29 | 2020-03-30 | Beijing Hanmi Pharmaceutical Co Ltd | Heterodimeric immunoglobulin constructs and preparation methods thereof |
| US20200140565A1 (en) | 2016-10-20 | 2020-05-07 | I-Mab | Novel cd47 monoclonal antibodies and uses thereof |
| CA3042581A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Enhancement of cd47 blockade therapy by proteasome inhibitors |
| WO2018081898A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Improvements in cd47 blockade therapy by hdac inhibitors |
| CN106519036B (zh) * | 2016-11-04 | 2019-06-11 | 新乡医学院 | 抗cd47和egfr的双功能蛋白及其制备方法与应用 |
| WO2018090950A1 (zh) | 2016-11-18 | 2018-05-24 | 北京韩美药品有限公司 | 抗pd‐1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 |
| CN108220228A (zh) * | 2016-12-09 | 2018-06-29 | 上海迈泰君奥生物技术有限公司 | 无血清细胞培养基及高效表达重组蛋白质的方法 |
| ES2916217T3 (es) | 2017-01-05 | 2022-06-29 | Kahr Medical Ltd | Una proteína de fusión SIRP1 ALPHA-41BBL y métodos de uso de la misma |
| US11299530B2 (en) | 2017-01-05 | 2022-04-12 | Kahr Medical Ltd. | SIRP alpha-CD70 fusion protein and methods of use thereof |
| DK3565579T3 (da) | 2017-01-05 | 2023-09-04 | Kahr Medical Ltd | Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf |
| US11566060B2 (en) | 2017-01-05 | 2023-01-31 | Kahr Medical Ltd. | PD1-CD70 fusion protein and methods of use thereof |
| US11267856B2 (en) | 2017-02-27 | 2022-03-08 | Shattuck Labs, Inc. | CSF1R-CD40L chimeric proteins |
| JP7244428B2 (ja) | 2017-02-27 | 2023-03-22 | シャタック ラボ，インコーポレイテッド | Ｖｓｉｇ８ベースのキメラタンパク質 |
| IL268198B2 (en) | 2017-02-27 | 2024-10-01 | Shattuck Labs Inc | Tigit- and light-based chimeric proteins |
| CN108623689B (zh) * | 2017-03-15 | 2020-10-16 | 宜明昂科生物医药技术（上海）有限公司 | 新型重组双功能融合蛋白及其制备方法和用途 |
| US11725210B2 (en) | 2017-03-17 | 2023-08-15 | Fred Hutchinson Cancer Center | Immunomodulatory fusion proteins and uses thereof |
| CN108864290B (zh) * | 2017-05-08 | 2021-12-07 | 上海津曼特生物科技有限公司 | 双特异性重组蛋白及其应用 |
| CN111448323B (zh) * | 2017-06-07 | 2023-12-01 | 长源赋能(上海)生命科技有限公司 | 精确制导的多功能治疗抗体 |
| MX2020001309A (es) | 2017-08-02 | 2020-08-20 | Phanes Therapeutics Inc | Anticuerpos anti-cd47 y sus usos. |
| WO2019043059A1 (en) * | 2017-08-30 | 2019-03-07 | Symphogen A/S | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER BY ANTI-EGFR ANTIBODIES |
| WO2019047885A1 (en) * | 2017-09-07 | 2019-03-14 | Dingfu Biotarget Co., Ltd. | IMMUNOCONJUGATES COMPRISING ALPHA REGULATORY SIGNAL PROTEIN |
| WO2019066536A1 (ko) * | 2017-09-28 | 2019-04-04 | 한국과학기술연구원 | 신규 암 치료용 조성물 |
| CN119264274A (zh) * | 2017-10-12 | 2025-01-07 | 免疫苏醒公司 | Vegfr-抗体轻链融合蛋白 |
| CN111278865B (zh) * | 2017-10-26 | 2023-04-25 | 盛禾(中国)生物制药有限公司 | 新的重组融合蛋白及其制备和用途 |
| KR102366853B1 (ko) * | 2017-11-10 | 2022-02-23 | 아이-맵 바이오파마 유에스 리미티드 | Cd47 항체 및 사이토카인을 포함하는 융합 단백질 |
| US12110332B2 (en) | 2017-11-20 | 2024-10-08 | Taizhou Mabtech Pharmaceutical Co., Ltd. | Bifunctional fusion protein targeting CD47 and PD-L1 |
| CA3084626A1 (en) | 2017-12-04 | 2019-06-13 | Beijing Hanmi Pharmaceutical Co., Ltd. | Anti-pd-l1/anti-cd47 bispecific antibody with structure like natural antibody and in form of heterodimer and preparation thereof |
| WO2019109357A1 (zh) * | 2017-12-08 | 2019-06-13 | 杭州翰思生物医药有限公司 | 抗pd-1/cd47的双特异性抗体及其应用 |
| WO2019153200A1 (zh) | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 |
| EP3765080A4 (en) * | 2018-03-13 | 2022-03-16 | Trillium Therapeutics Inc. | IMPROVEMENTS IN THERAPY FOR CD47 BLOCKADE BY EGFR ANTIBODIES |
| WO2019183266A1 (en) | 2018-03-21 | 2019-09-26 | ALX Oncology Inc. | Antibodies against signal-regulatory protein alpha and methods of use |
| CN110386984B (zh) * | 2018-04-17 | 2022-04-22 | 杭州尚健生物技术有限公司 | 结合cd47蛋白的融合蛋白及其应用 |
| CN108794641A (zh) * | 2018-07-04 | 2018-11-13 | 上海科医联创生物科技有限公司 | 一种针对EGFRvIII的多功能融合蛋白及其应用 |
| CA3104780A1 (en) * | 2018-07-11 | 2020-01-16 | Kahr Medical Ltd. | Sirpalpha-4-1bbl variant fusion protein and methods of use thereof |
| IL280102B1 (en) | 2018-07-11 | 2026-07-01 | Kahr Medical Ltd | Fusion protein containing PD1-4-1BBL and methods of using the same |
| JP7193058B2 (ja) * | 2018-08-08 | 2022-12-20 | イミューンオンコ バイオファーマシューティカルズ （シャンハイ） インコーポレイテッド | Ｃｄ４７およびｈｅｒ２を標的とする組換え二機能性タンパク質 |
| JP2022512540A (ja) | 2018-08-29 | 2022-02-07 | シャタック ラボ，インコーポレイテッド | Ｆｌｔ３ｌ系キメラタンパク質 |
| EP3846855B1 (en) | 2018-09-04 | 2024-12-04 | Pfizer Inc. | Cd47 blockade with parp inhibition for disease treatment |
| CN109535258A (zh) * | 2018-10-26 | 2019-03-29 | 上海科弈药业科技有限公司 | 一种针对Her2+肿瘤的多功能融合蛋白及其应用 |
| GB2596411B (en) * | 2018-10-29 | 2023-09-20 | Tigatx Inc | Compositions and methods comprising IgA antibody constructs |
| CN111303293B (zh) * | 2018-11-14 | 2022-08-30 | 杭州尚健生物技术有限公司 | 一种融合蛋白及其用途 |
| EP3880248A4 (en) * | 2018-11-14 | 2022-08-10 | JN Biosciences, LLC | MULTIMERIC HYBRID FC PROTEINS FOR IV IG REPLACEMENT |
| CN113412279B (zh) * | 2018-11-15 | 2024-09-24 | 拜奥迪斯私人有限公司 | 人源化抗SIRPα抗体 |
| CN109517054B (zh) * | 2018-12-04 | 2022-04-08 | 江苏东抗生物医药科技有限公司 | SIRPα变体或其融合蛋白及其应用 |
| CN109535263B (zh) * | 2018-12-04 | 2022-06-17 | 江苏东抗生物医药科技有限公司 | SIRPα突变体及其融合蛋白 |
| US20220056135A1 (en) * | 2018-12-21 | 2022-02-24 | Ose Immunotherapeutics | Bifunctional anti-pd-1/sirpa molecule |
| EP3936526A4 (en) * | 2019-03-06 | 2023-03-08 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | BIFUNCTIONAL FUSION PROTEIN AND PHARMACEUTICAL USE THEREOF |
| CN111763261B (zh) * | 2019-04-02 | 2022-08-09 | 杭州尚健生物技术有限公司 | 一种融合蛋白及其用途 |
| TW202104260A (zh) * | 2019-04-05 | 2021-02-01 | 美商西建公司 | 腫瘤選擇性結合ｃｄ４７之抗體之工程 |
| CA3141130A1 (en) | 2019-05-31 | 2020-12-03 | ALX Oncology Inc. | Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor |
| CN114222586A (zh) * | 2019-06-14 | 2022-03-22 | 斯克里普斯研究学院 | 免疫检查点阻断性双特异性分子 |
| CN114072426B (zh) * | 2019-07-08 | 2024-01-26 | 南京金斯瑞生物科技有限公司 | 抗cd47/抗pd-1双特异抗体及其制备方法和应用 |
| AU2020315598B2 (en) | 2019-07-16 | 2024-12-12 | Gilead Sciences, Inc. | HIV vaccines and methods of making and using |
| EP4039711A4 (en) * | 2019-07-23 | 2023-11-15 | Nanjing GenScript Biotech Co., Ltd. | Anti-cd47/anti-lag-3 bispecific antibody, preparation method therefor and use thereof |
| JP7723420B2 (ja) * | 2019-08-28 | 2025-08-14 | キングス・カレッジ・ロンドン | Ｂ細胞標的化並列ＣＡＲ（ｐＣＡＲ）治療的薬剤 |
| PH12022550835A1 (en) | 2019-10-18 | 2023-07-03 | Forty Seven Inc | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| NZ786589A (en) | 2019-10-31 | 2025-03-28 | Forty Seven Llc | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| CN115038718B (zh) * | 2019-11-08 | 2024-07-02 | 山东先声生物制药有限公司 | 抗人程序性死亡配体-1（pd-l1）的抗体及其用途 |
| WO2021108693A1 (en) | 2019-11-27 | 2021-06-03 | ALX Oncology Inc. | Combination therapies for treating cancer |
| CN115362003B (zh) | 2019-12-24 | 2024-03-22 | 卡尔那生物科学株式会社 | 二酰基甘油激酶调节化合物 |
| TWI890283B (zh) | 2020-02-14 | 2025-07-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| US12091681B2 (en) | 2020-03-27 | 2024-09-17 | Mendus B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| WO2022003568A1 (en) | 2020-06-30 | 2022-01-06 | Dcprime B.V. | Use of leukemia-derived cells in ovarian cancer vaccines |
| CN111808183B (zh) * | 2020-07-25 | 2022-07-08 | 北京吉尔麦迪生物医药科技有限公司 | 一种靶向CD47的高亲和力SIRPα突变体及其融合蛋白 |
| CA3193073A1 (en) * | 2020-09-17 | 2022-03-24 | Liping SONG | Bispecific recombinant protein and use thereof |
| JP2023545983A (ja) * | 2020-10-07 | 2023-11-01 | セルジーン コーポレイション | リンパ系悪性腫瘍状態の二重特異性抗体治療 |
| WO2022120286A1 (en) * | 2020-12-06 | 2022-06-09 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| CN112708675A (zh) * | 2020-12-25 | 2021-04-27 | 中山大学肿瘤防治中心 | 骨髓nk细胞联合mcl1抑制剂在抗白血病中的应用 |
| CN112656941A (zh) * | 2021-01-20 | 2021-04-16 | 福建医科大学附属协和医院 | 抗cd47单克隆抗体在制备抗阿霉素耐药的急性淋巴细胞白血病细胞的药物中应用 |
| WO2022190058A1 (en) | 2021-03-12 | 2022-09-15 | Dcprime B.V. | Methods of vaccination and use of cd47 blockade |
| EP4320156A1 (en) * | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN117355531A (zh) | 2021-06-23 | 2024-01-05 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| WO2023003331A1 (en) * | 2021-07-19 | 2023-01-26 | Yuhan Corporation | Sirp-alpha variants and use thereof |
| CN120329453A (zh) * | 2021-07-19 | 2025-07-18 | 百奥泰生物制药股份有限公司 | 基于Luciferase报告基因系统的重组嵌合膜蛋白及其应用 |
| CN113956363B (zh) * | 2021-10-13 | 2023-03-31 | 宜明昂科生物医药技术（上海）股份有限公司 | 靶向cd47和cd24的重组融合蛋白及其制备和用途 |
| EP4423078A1 (en) | 2021-10-28 | 2024-09-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| WO2023072217A1 (en) * | 2021-10-28 | 2023-05-04 | Guangzhou Lintonpharm Co., Ltd. | Fusion proteins targeting cd3 and cd47 |
| PE20241186A1 (es) | 2021-10-29 | 2024-06-03 | Gilead Sciences Inc | Compuestos de cd73 |
| WO2023079438A1 (en) | 2021-11-08 | 2023-05-11 | Pfizer Inc. | Enhancement of cd47 blockade therapy with anti-vegf agents |
| EP4319796A4 (en) * | 2021-12-21 | 2025-07-23 | Fbd Biologics Ltd | MODIFIED SIRPalpha VARIANTS AND METHODS OF USE THEREOF |
| CN118488948A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| US20240124412A1 (en) | 2021-12-22 | 2024-04-18 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| AU2022435471A1 (en) * | 2022-01-18 | 2024-05-30 | Fbd Biologics Limited | Cd47/pd-l1-targeting protein complex and methods of use thereof |
| CA3248911A1 (en) | 2022-01-28 | 2023-08-03 | Gilead Sciences, Inc. | POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS |
| PL4245756T3 (pl) | 2022-03-17 | 2025-02-17 | Gilead Sciences, Inc. | Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania |
| AU2023240346A1 (en) | 2022-03-24 | 2024-09-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| WO2023183890A1 (en) * | 2022-03-24 | 2023-09-28 | Bitterroot Bio, Inc. | Multivalent sirp-alpha fusion polypeptides |
| JP2025510774A (ja) | 2022-03-24 | 2025-04-15 | ビタールート・バイオ・インコーポレイテッド | 修飾ｆｃドメインを有するｓｉｒｐ－ａｌｐｈａ融合ポリペプチド |
| KR20240162568A (ko) * | 2022-03-25 | 2024-11-15 | 우시 바이올로직스 아일랜드 리미티드 | 항-her2/항-cd47 분자 및 이의 용도 |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| EP4511127A1 (en) | 2022-04-21 | 2025-02-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| CN120923632A (zh) * | 2022-05-06 | 2025-11-11 | 正大天晴药业集团股份有限公司 | 靶向cd40和cd47的重组融合蛋白 |
| US11807689B1 (en) * | 2022-06-01 | 2023-11-07 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11814439B1 (en) | 2022-06-01 | 2023-11-14 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11965032B1 (en) | 2022-06-01 | 2024-04-23 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11884740B1 (en) | 2022-06-01 | 2024-01-30 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| AU2023285109A1 (en) * | 2022-06-10 | 2024-12-12 | Incyte Corporation | Combination therapy comprising sirp alpha fusion protein and anti-cd19 antibody for treatment of cancer |
| WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
| CA3259040A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | HIV Immunogenic Polypeptides and Vaccines and Their Uses |
| CN116041470B (zh) * | 2022-08-04 | 2024-10-22 | 四川大学华西医院 | 具有高亲和力结合肿瘤细胞cd47的细胞膜材料及其制备方法和应用 |
| US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
| EP4592316A1 (en) * | 2022-09-23 | 2025-07-30 | Lindis Biotech GmbH | Isolated antigen-binding protein and use thereof |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN118546255A (zh) * | 2023-02-24 | 2024-08-27 | 恒翼生物医药(上海)股份有限公司 | 一种靶向αvβ3和CD47的双功能融合蛋白以及其应用 |
| EP4683654A1 (en) * | 2023-03-22 | 2026-01-28 | Li, Wangzhi | Sirp variants and uses thereof |
| WO2024215754A1 (en) | 2023-04-11 | 2024-10-17 | Gilead Sciences, Inc. | Kras modulating compounds |
| PE20260121A1 (es) | 2023-04-21 | 2026-01-16 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| WO2024245380A1 (en) | 2023-05-31 | 2024-12-05 | Fbd Biologics Limited | Cd47/pd-l1-targeting protein complex and methods of use thereof |
| JP2026522894A (ja) | 2023-06-30 | 2026-07-09 | ギリアード サイエンシーズ， インコーポレイテッド | Ｋｒａｓ調節化合物 |
| AU2024297978A1 (en) | 2023-07-26 | 2026-02-05 | Gilead Sciences, Inc. | Parp7 inhibitors |
| CN121568935A (zh) | 2023-07-26 | 2026-02-24 | 吉利德科学公司 | Parp7抑制剂 |
| EP4774280A1 (en) | 2023-09-08 | 2026-07-15 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025096589A1 (en) | 2023-11-03 | 2025-05-08 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025247303A1 (zh) * | 2024-05-30 | 2025-12-04 | 上海艾乐晞生物科技有限公司 | 具有pH依赖结合活性的人信号调节蛋白α突变体及其应用 |
| US20260098049A1 (en) | 2024-08-12 | 2026-04-09 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20260130893A1 (en) | 2024-10-21 | 2026-05-14 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2026136515A1 (en) | 2024-12-19 | 2026-06-25 | Gilead Sciences, Inc. | Parp7 inhibitors |
| CN121824730A (zh) * | 2026-03-09 | 2026-04-10 | 上海荣昌生物科技有限公司 | 一种多肽、融合蛋白、双特异性抗体及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9930706D0 (en) | 1999-12-24 | 2000-02-16 | Medical Res Council | Composition for inhibiting macrophage activity |
| US20090191202A1 (en) * | 2005-09-29 | 2009-07-30 | Jamieson Catriona Helen M | Methods for manipulating phagocytosis mediated by CD47 |
| WO2007062037A2 (en) | 2005-11-21 | 2007-05-31 | Laboratoires Serono Sa | Compositions and methods of producing hybrid antigen binding molecules and uses thereof |
| AT503889B1 (de) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
| JP2011500005A (ja) | 2007-10-11 | 2011-01-06 | ユニバーシティー ヘルス ネットワーク | ヒト造血幹細胞の生着を増加させるためのＳＩＲＰα−ＣＤ４７相互作用の調節およびそのための化合物 |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| BRPI0923442A2 (pt) | 2008-12-19 | 2016-01-12 | Novartis Ag | polipeptídeos solúveis para uso em tratamento de distúrbio autoimunes e inflamatórios. |
| DK2429574T3 (da) * | 2009-05-15 | 2015-06-22 | Univ Health Network | Sammensætninger og fremgangsmåder til behandling af hæmatologiske cancere der targeterer sirp-cd47-interaktionen |
| SI2477648T1 (sl) | 2009-09-15 | 2022-09-30 | The Board Of Trustees Of The Leland Stanford Junior University | Sinergijska terapija proti CD47 za krvne rake |
| AU2011252851B2 (en) | 2010-05-14 | 2016-10-06 | The Board Of Trustees Of The Leland Stanford Junior University | Humanized and chimeric monoclonal antibodies to CD47 |
| EP2407487A1 (en) | 2010-07-14 | 2012-01-18 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Multispecific modular antibody |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| EP3766511A1 (en) | 2012-01-17 | 2021-01-20 | The Board of Trustees of the Leland Stanford Junior University | High affinity sirp-alpha reagents |
| ME03550B (me) | 2012-12-17 | 2020-07-20 | Trillium Therapeutics Inc | Lečenje cd47+ obolelih ćelija sa sirp alfa-fc fuzijama |
| WO2014121093A1 (en) * | 2013-01-31 | 2014-08-07 | Thomas Jefferson University | Fusion proteins that facilitate cancer cell destruction |
| EP2970485A1 (en) | 2013-03-15 | 2016-01-20 | Merck Patent GmbH | Tetravalent bispecific antibodies |
| JP6355032B2 (ja) | 2014-03-24 | 2018-07-11 | イミューンオンコ バイオファーマシューティカルズ （シャンハイ） カンパニー リミテッド | 新規組換え二機能性融合タンパク質、それらの調製および使用 |
| EP3188758B1 (en) | 2014-08-08 | 2023-10-04 | The Board of Trustees of the Leland Stanford Junior University | Sirp alpha-antibody fusion proteins |
| ES2751915T5 (es) | 2014-08-15 | 2022-12-23 | Merck Patent Gmbh | Proteínas de fusión de inmunoglobulina con SIRP alfa |
-
2015
- 2015-08-14 ES ES15750744T patent/ES2751915T5/es active Active
- 2015-08-14 MX MX2017001712A patent/MX377196B/es active IP Right Grant
- 2015-08-14 RU RU2017108203A patent/RU2017108203A/ru not_active Application Discontinuation
- 2015-08-14 SI SI201530975T patent/SI3180363T1/sl unknown
- 2015-08-14 EP EP15750744.3A patent/EP3180363B2/en active Active
- 2015-08-14 CN CN201580054385.2A patent/CN107108748A/zh active Pending
- 2015-08-14 AU AU2015303135A patent/AU2015303135B2/en not_active Ceased
- 2015-08-14 HU HUE15750744A patent/HUE046661T2/hu unknown
- 2015-08-14 PL PL15750744T patent/PL3180363T3/pl unknown
- 2015-08-14 SG SG11201701189TA patent/SG11201701189TA/en unknown
- 2015-08-14 EP EP19198866.6A patent/EP3643727A1/en not_active Withdrawn
- 2015-08-14 US US14/827,003 patent/US11021694B2/en not_active Expired - Fee Related
- 2015-08-14 BR BR112017002646-5A patent/BR112017002646A2/pt not_active IP Right Cessation
- 2015-08-14 LT LT15750744T patent/LT3180363T/lt unknown
- 2015-08-14 DK DK15750744T patent/DK3180363T3/da active
- 2015-08-14 JP JP2017508075A patent/JP6764858B2/ja not_active Expired - Fee Related
- 2015-08-14 WO PCT/EP2015/068798 patent/WO2016024021A1/en not_active Ceased
- 2015-08-14 HR HRP20191872TT patent/HRP20191872T1/hr unknown
- 2015-08-14 CA CA2956126A patent/CA2956126A1/en active Pending
- 2015-08-14 PT PT157507443T patent/PT3180363T/pt unknown
- 2015-08-14 KR KR1020177006711A patent/KR20170036796A/ko not_active Ceased
-
2017
- 2017-02-15 IL IL250622A patent/IL250622B2/en unknown
- 2017-03-14 ZA ZA2017/01810A patent/ZA201701810B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017108203A (ru) | Слитые белки sirp-альфа с иммуноглобулином | |
| RU2018142544A (ru) | Биспецифические связывающие белки и пути их применения | |
| JP2020063262A5 (enExample) | ||
| RU2015144098A (ru) | Четырехвалентные биспецифические антитела | |
| JP2017506217A5 (enExample) | ||
| FI3459597T3 (fi) | Yksiketjuinen vasta-aine ctla4:lle ja siitä johdettu proteiini | |
| JP2018508214A5 (enExample) | ||
| JP2019532619A5 (enExample) | ||
| FI3826667T3 (fi) | Claudin6 vasta-aineita ja menetelmiä syövän hoitamiseksi | |
| JP2019524693A5 (enExample) | ||
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| FI3579848T3 (fi) | Monispesifisiä sitovia proteiineja luonnollisten tappajasolujen aktivointiin ja niiden terapeuttisia käyttöjä syövän hoitoon | |
| JP2012523848A5 (enExample) | ||
| JP2020506971A5 (enExample) | ||
| JP2018517431A5 (enExample) | ||
| JP2019500011A5 (enExample) | ||
| JP2017527274A5 (enExample) | ||
| RU2021114500A (ru) | НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ | |
| JP2018503380A5 (enExample) | ||
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
| JP2017520575A5 (enExample) | ||
| HRP20170462T1 (hr) | Protutijela za epidermalni receptor 3 faktora rasta (her3) | |
| JP2017504578A5 (enExample) | ||
| PE20220763A1 (es) | Materiales y metodos para modular la inmunidad mediada por celulas t | |
| JP2018530331A5 (enExample) |